Latest news

• Merck & Co's cancer drug Keytruda gaining traction in US

  Merck's third-quarter results were hit as expected by the lingering effect of patent expiries on key products such as cancer drug Temodar (temozolomide) and Singulair (montelukast) for asthma, as

• Merck cuts MK-3475 deals with Pfizer, Amgen and Incyte

  sales of asthma drug Singulair (montelukast) on generic competition, as well as a 14 per cent drop in net income to $781m.

• GSK loses patent on Tykerb in India

  This year has already seen IP setbacks in India for Novartis' leukaemia drug Glivec (imatinib), Merck &Co's Januvia (sitagliptin) diabetes franchise and Singulair (montelukast),   Roche's Pegasys (peginterferon alfa-2a),

• Merck profit slides as generics continue to bite

  montelukast), Maxalt (rizatriptan) for migraines, blood pressure treatment Cozaar (losartan) and antihistamine Clarinex (desloratadine).

• Merck wins injunction against Januvia generics in India

  regarding Roche's Pegasys (peginterferon alfa-2a), Merck &Co's Singulair (montelukast), Gilead Sciences' Viread (tenofovir), Pfizer's Sutent (sunitinib) and Bayer's Nexavar (sorafenib tosylate).